Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company PIC

Junshi Biosciences Achieves First‑Ever Semiannual Profitability as Toripalimab Sales Surge 36%

Fineline Cube Aug 27, 2026
Company Drug PIC

FDA Approves Revolution Medicines’ Rasonque (daraxonrasib), an Oral Multi‑Selective RAS(ON) Inhibitor, for Metastatic Pancreatic Cancer

Fineline Cube Aug 27, 2026
Company Drug PIC

NMPA Approves Novartis’ Pluvicto Plus ARPI for PSMA‑Positive mHSPC in China, Advancing Radioligand Therapy to Earlier Prostate Cancer

Fineline Cube Aug 26, 2026
Company Drug PIC

FDA Approves J&J’s IMAAVY for Warm Autoimmune Hemolytic Anemia, Marking Second Indication for Nipocalimab

Fineline Cube Aug 26, 2026
Company Drug PIC

FDA Approves BeOne’s Tevimbra Plus Zanidatamab and Chemotherapy for First‑Line HER2‑Positive Gastroesophageal Adenocarcinoma

Fineline Cube Aug 26, 2026
Company PIC

Junshi Biosciences Achieves First‑Ever Semiannual Profitability as Toripalimab Sales Surge 36%

Fineline Cube Aug 27, 2026
Company Drug

CSPC’s PD-1/IL-15 Bispecific SYS6090 (JMT108) Granted FDA Fast Track for MSS/pMMR Metastatic Colorectal Cancer

Fineline Cube Aug 27, 2026
Company

Insilico Medicine Swings to Profitability as Revenue Surges 287% in 1H 2026, Rentosertib Advances to Phase 3

Fineline Cube Aug 27, 2026
Company Drug

IMPACT Therapeutics Nominates KAT6A-Specific PROTAC IMP2794 as Preclinical Candidate From Proprietary TPD Platform

Fineline Cube Aug 13, 2026

IMPACT Therapeutics, Inc. (HKG: 7630) announced the nomination of IMP2794 as a preclinical candidate (PCC)...

Company Drug

Akeso’s Ivonescimab Wins NMPA Approval for First-Line Advanced Squamous Non-Small Cell Lung Cancer in Combination With Chemotherapy

Fineline Cube Aug 13, 2026

Akeso Biopharma (HKG: 9926) announced that the National Medical Products Administration (NMPA) of China has...

Company Deals

Allist Pharmaceuticals Secures Exclusive Greater China License for ArriVent’s Bispecific ADC AST12608/ARR-002

Fineline Cube Aug 13, 2026

Allist Pharmaceuticals (SHA: 688578) announced that it has signed a strategic collaboration agreement with ArriVent...

Company Deals

Kintor Pharmaceutical Grants Wellrise Exclusive Distribution Rights for KT-939 Raw Material in South Korea

Fineline Cube Aug 13, 2026

Kintor Pharmaceutical (HKG: 9939) announced that it has entered into an exclusive product distribution agreement...

Company Deals

CSPC Pharmaceutical Receives $30 Million Upfront From AstraZeneca Under siRNA Drug Discovery Partnership

Fineline Cube Aug 13, 2026

CSPC Pharmaceutical Group (HKG: 1093) announced that it has received a USD 30 million upfront...

Others

Laekna’s NDA for AKT Inhibitor Afuresertib Accepted by CDE in HR+/HER2‑ Breast Cancer After Qilu Licensing Deal

Fineline Cube Aug 12, 2026

Laekna Therapeutics Shanghai Co., Ltd. (HKG: 2105) announced that the New Drug Application (NDA) for...

Company Medical Device PIC

NMPA Approves Geneseeq’s Fandekang NTRK Fusion Detection Kit as Companion Diagnostic for Vcare PharmaTech’s Eratrectinib

Fineline Cube Aug 12, 2026

The National Medical Products Administration (NMPA) approved Geneseeq Technology Inc.‘s (a genetic cancer testing service...

Company Deals Digital PIC

Aureka Biotechnologies Closes USD 100 Million Series B to Scale AI‑Native Biological Foundation Models, Total Funding Nears USD 200 Million

Fineline Cube Aug 12, 2026

Aureka Biotechnologies, a global leader in the Tech-Bio space, announced the completion of a Series...

Company Drug R&D

Insilico Medicine Nominates ISM0900, AI‑Designed Oral Lp(a) Inhibitor, as 9th Preclinical Candidate of 2026

Fineline Cube Aug 12, 2026

Insilico Medicine (HKG: 3696) announced the nomination of ISM0900 — a potent, highly selective, oral...

Company Medical Device

Haohai Wins NMPA Approval for China’s First Domestic Trifocal Toric Intraocular Lens for Cataract Patients With Astigmatism

Fineline Cube Aug 12, 2026

Shanghai Haohai Biological Technology Co. Ltd. (SHA: 688366) announced that its trifocal toric intraocular lens...

Company Drug

Wantai’s 9‑Valent HPV Vaccine Wins Thailand Approval – China’s First and World’s Second 9vHPV Vaccine Expands Into Southeast Asia

Fineline Cube Aug 12, 2026

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHA: 603392) announced that its self‑developed 9‑valent human...

Company Deals

Mabwell Signs Licensing Deals With Southeast Asia Partners for Aflibercept Biosimilar 9MW0813 in Philippines, Vietnam, and Malaysia

Fineline Cube Aug 12, 2026

Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062, HKG: 2493) announced that it has entered into...

Company Deals PIC

MSD Signs Oncology Collaboration With InventisBio Through MCICC to Accelerate Small‑Molecule Clinical Development

Fineline Cube Aug 12, 2026

Merck & Co., Inc. (MSD; NYSE: MRK) announced that it has signed a collaboration agreement...

Company Deals PIC

Sanyou Biopharmaceuticals Signs Strategic Deal With Baiyunshan Xihe to Co‑Develop Novel Radiopharmaceuticals

Fineline Cube Aug 12, 2026

Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. and Guangzhou Baiyunshan Xihe Health Medicine Co., Ltd. announced the...

Company Deals PIC

IMPACT Therapeutics Signs Exclusive Deal With Pharmanovia for Senaparib PARP Inhibitor Across 66 Countries Worth Up to EUR 423.5 Million

Fineline Cube Aug 12, 2026

IMPACT Therapeutics, Inc. (HKG: 7630) announced an exclusive partnership with Pharmanovia for senaparib (brand name:...

Company Deals

Essex Bio-Technology Signs Strategic Framework With Gunze Medical to Expand FGF-2 Regenerative Medicine Access Across Asia

Fineline Cube Aug 12, 2026

Essex Bio-Technology (HKG: 1061) announced a strategic collaboration framework agreement with Gunze Medical Limited to...

Company Deals PIC

CanSino Biologics Reaches Cooperation Intent With Pakistan’s AGP Limited on PCV13i Pneumococcal Vaccine

Fineline Cube Aug 12, 2026

CanSino Biologics (HKG: 6185) announced that it reached a cooperation intent with its Pakistani partner...

Company Deals

Tempest Therapeutics Signs Strategic Partnership With Senlang to Advance TPST‑4003 In Vivo CAR‑T Candidate in China

Fineline Cube Aug 12, 2026

Tempest Therapeutics, Inc. (NASDAQ: TPST) announced a strategic partnership with Hebei Senlang Biotechnology Co., Ltd....

Company Deals

Zhaoke Ophthalmology Signs Strategic MOU With Brazil’s Teuto at BIO 2026 – First Latin America Eye‑Care Market Entry

Fineline Cube Aug 12, 2026

Zhaoke Ophthalmology Limited (HKG: 6622) announced that it signed a strategic cooperation memorandum with Brazilian...

Company Deals PIC

GRIT Biotechnology and Drug Farm Sign Deep Collaboration Agreement to Co‑Create KunEvo, an AI‑Native Biotech R&D Platform for First‑in‑Class Drug Discovery

Fineline Cube Aug 11, 2026

GRIT Biotechnology and Sino-US biotech company Drug Farm jointly announced a deep agreement to collaborate...

Posts pagination

1 … 5 6 7 … 712

Recent updates

  • CSPC’s PD-1/IL-15 Bispecific SYS6090 (JMT108) Granted FDA Fast Track for MSS/pMMR Metastatic Colorectal Cancer
  • Insilico Medicine Swings to Profitability as Revenue Surges 287% in 1H 2026, Rentosertib Advances to Phase 3
  • Huadong Medicine’s ROR1 ADC HDM2005 Granted FDA Fast Track Designation — First Domestic ROR1 ADC to Achieve the Status
  • Micot’s First‑in‑Class TrkB Agonist MT200605 Meets Primary Endpoint in Phase 2 Acute Ischemic Stroke Trial
  • NMPA Suspends Sales and Use of Pierre Fabre’s Encorafenib Capsules Over Unapproved Manufacturing Change
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

CSPC’s PD-1/IL-15 Bispecific SYS6090 (JMT108) Granted FDA Fast Track for MSS/pMMR Metastatic Colorectal Cancer

Company

Insilico Medicine Swings to Profitability as Revenue Surges 287% in 1H 2026, Rentosertib Advances to Phase 3

Company Drug

Huadong Medicine’s ROR1 ADC HDM2005 Granted FDA Fast Track Designation — First Domestic ROR1 ADC to Achieve the Status

Company Drug

Micot’s First‑in‑Class TrkB Agonist MT200605 Meets Primary Endpoint in Phase 2 Acute Ischemic Stroke Trial

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2026 | Fineline Information & Technology | BlogData by Themeansar.